Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer

Published:2014-03-05 Issue:4 Volume:31 Page:
ISSN:1357-0560
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Dirican Ahmet,Kucukzeybek Yuksel,Alacacioglu Ahmet,Varol Umut,Aksun Saliha,Bayoglu Ibrahim Vedat,Demir Lutfiye,Coban Eyup,Sutcu Recep,Tarhan Mustafa Oktay

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12032-014-0905-8.pdf

Reference39 articles.

1. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008;26:689.

2. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44.

3. Lievre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepere C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer. 2009;9:347.

4. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res. 2008;14:6371–5.

5. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updates. 2008;11:219–30.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis;Anticancer Research;2022-08-23

2. Epithelial–mesenchymal transition‐related serum markers ET‐1, IL‐8 and TGF‐β2 are elevated in a Finnish wet age‐related macular degeneration cohort;Acta Ophthalmologica;2021-10-26

3. Targeting endothelin 1 receptor-miR-200b/c-ZEB1 circuitry blunts metastatic progression in ovarian cancer;Communications Biology;2020-11-13

4. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT];PLOS ONE;2020-03-06

5. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial);European Journal of Cancer;2019-01